Seer (NASDAQ:SEER) CFO Sells $12,342.07 in Stock

Seer, Inc. (NASDAQ:SEERGet Free Report) CFO David Horn sold 7,303 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $1.69, for a total transaction of $12,342.07. Following the completion of the sale, the chief financial officer owned 493,959 shares of the company’s stock, valued at approximately $834,790.71. The trade was a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Seer Price Performance

Shares of NASDAQ SEER traded up $0.09 during trading on Thursday, hitting $1.77. The stock had a trading volume of 215,435 shares, compared to its average volume of 333,711. Seer, Inc. has a 12 month low of $1.65 and a 12 month high of $2.41. The company has a market capitalization of $99.87 million, a PE ratio of -1.43 and a beta of 1.63. The firm has a fifty day moving average of $1.80 and a two-hundred day moving average of $1.88.

Seer (NASDAQ:SEERGet Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.30). Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%. The firm had revenue of $2.79 million during the quarter, compared to analyst estimates of $3.60 million.

Analyst Ratings Changes

Several equities analysts recently weighed in on SEER shares. Canaccord Genuity Group started coverage on shares of Seer in a research report on Monday, May 4th. They set a “buy” rating and a $4.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research report on Tuesday, April 21st. Finally, TD Cowen raised shares of Seer to a “strong-buy” rating in a research report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $4.00.

Get Our Latest Stock Report on SEER

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Seer by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company’s stock worth $4,820,000 after acquiring an additional 18,760 shares during the last quarter. Bridgeway Capital Management LLC boosted its position in Seer by 15.5% during the second quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company’s stock worth $1,792,000 after purchasing an additional 112,100 shares during the period. Nano Cap New Millennium Growth Fund L P bought a new position in Seer during the fourth quarter worth about $1,510,000. Geode Capital Management LLC boosted its position in Seer by 16.5% during the second quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock worth $1,091,000 after purchasing an additional 72,265 shares during the period. Finally, Jane Street Group LLC boosted its position in Seer by 33.3% during the first quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock worth $430,000 after purchasing an additional 63,432 shares during the period. Institutional investors own 75.20% of the company’s stock.

About Seer

(Get Free Report)

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.

See Also

Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.